Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference

Rhea-AI Summary

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, announced CEO James Porter will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 2:35 p.m. ET in Boston. Nuvalent focuses on developing targeted therapies for cancer, leveraging expertise in chemistry and drug design to combat resistance and minimize adverse effects. A live webcast of the event will be accessible on their website, with an archive available for 30 days.

News Market Reaction – NUVL

+0.59%

+0.59% Session move

In the trading session that priced this news, NUVL gained 0.59%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022, at 2:35 p.m. ET in Boston.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-wells-fargo-2022-healthcare-conference-301615855.html

SOURCE Nuvalent, Inc.

FAQ

When will Nuvalent participate in the Wells Fargo 2022 Healthcare Conference?

Nuvalent will participate in the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 2:35 p.m. ET.

Who is speaking at the Wells Fargo 2022 Healthcare Conference for Nuvalent?

James Porter, Ph.D., the CEO of Nuvalent, will speak at the conference.

Where can I watch the Nuvalent conference presentation?

The presentation will be available via a live webcast on Nuvalent's website.

What is the focus of Nuvalent's drug development?

Nuvalent focuses on creating precisely targeted therapies for patients with cancer, particularly for ROS1-positive and ALK-positive non-small cell lung cancer.

How long will the Nuvalent conference presentation be archived?

The webcast of the presentation will be archived for 30 days following the event.